Stockscreener 앱 받기
11.24
0.72%
0.08
시간 외 거래:
11.06
-0.18
-1.60%
Dyne Therapeutics Inc 주식(DYN)의 최신 뉴스
Short Interest Drops in Dyne Therapeutics Inc. After RallySafe Entry Stock Watch Suggestions for Cautious Traders - beatles.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN - GlobeNewswire Inc.
Is Dyne Therapeutics Reaching New Heights? - StocksToTrade
Dyne Therapeutics price target lowered to $13 from $34 at Oppenheimer - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - cnhinews.com
Oppenheimer Lowers Dyne Therapeutics (DYN) Price Target to $13.00 | DYN Stock News - GuruFocus
Oppenheimer Lowers Dyne Therapeutics (DYN) Price Target to $13.0 - GuruFocus
Dyne Therapeutics (DYN) Earns Breakthrough Therapy Status for DY - GuruFocus
Dyne Therapeutics Shares Rise 3.6% After FDA Grants Breakthrough Therapy Status - MSN
Dyne Reports Wider Loss in Fiscal Q2 - AOL.com
Dyne Therapeutics stock gains as DYNE-251 receives FDA breakthrough designation - Investing.com Canada
Dyne Therapeutics (DYN) Gains FDA Breakthrough Status for DYNE-2 - GuruFocus
Dyne Therapeutics stock rises after FDA grants breakthrough therapy status By Investing.com - Investing.com Australia
Dyne Therapeutics stock rises after FDA grants breakthrough therapy status - Investing.com
Dyne gets FDA breakthrough therapy status for DMD therapy - Seeking Alpha
Dyne Therapeutics (DYN) Earns Breakthrough Therapy Status for DYNE-251 - GuruFocus
Dyne Therapeutics Gains FDA Breakthrough Designation for DYNE-251 - TipRanks
Dyne Therapeutics Announces Breakthrough Therapy Designation For DYNE-251 - Nasdaq
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation - GuruFocus
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation For Dyne-251 In Duchenne Muscular Dystrophy - TradingView
Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy - Quiver Quantitative
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) - The Manila Times
Dyne Therapeutics Announces FDA Breakthrough Therapy - GlobeNewswire
FDA Breakthrough: DYNE-251 DMD Drug Could Transform Treatment by 2026 - Stock Titan
What makes Dyne Therapeutics Inc. stock price move sharplyAchieve breakthrough profits with expert advice - Jammu Links News
What is Dyne Therapeutics Inc. company’s growth strategyTremendous growth opportunities - Jammu Links News
Is it the right time to buy Dyne Therapeutics Inc. stockMarket-beating returns - Jammu Links News
Why is Dyne Therapeutics Inc. stock attracting strong analyst attentionAchieve breakthrough gains with expert advice - Jammu Links News
Should I hold or sell Dyne Therapeutics Inc. stock in 2025Build wealth steadily with proven investment techniques - Jammu Links News
What is the risk reward ratio of investing in Dyne Therapeutics Inc. stockAchieve breakthrough investment performance - Jammu Links News
How many analysts rate Dyne Therapeutics Inc. as a “Buy”Unlock powerful market insights for success - jammulinksnews.com
Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? - MSN
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - ADVFN Brasil
Pomerantz Investigates Dyne Therapeutics for Securities Fraud. - AInvest
Stifel Downgrades Dyne Therapeutics to Buy, Lowers PT to $36. - AInvest
Stifel lowers Dyne Therapeutics stock price target to $36 on endpoint changes - Investing.com Canada
Dyne Therapeutics (DYN) Gets a Buy from Scotiabank - The Globe and Mail
Dyne Therapeutics (DYN) Keeps 'Outperform' Rating Amid RBC Capital Price Target Cut to $23.00 - AInvest
Dyne Therapeutics Analysts Lower Forecasts Following Q2 Loss - AInvest
Dyne Therapeutics Advances in Neuromuscular Therapies - The Globe and Mail
Dyne Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingCapital Protection Trading Strategies Gain Interest - metal.it
Dyne Therapeutics Inc. stock prediction for this weekBuy Signal Based on Chart Analysis Confirmed - metal.it
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss - Benzinga
Dyne Therapeutics (DYN) Maintains Rating as RBC Capital Lowers P - GuruFocus
Dyne Therapeutics' Funding to Sustain Operations Through 2027, With Key Milestones Ahead - AInvest
Dyne Therapeutics Advances Clinical Programs and Strengthens Financial Position, with 349.45% Upside Potential - AInvest
Dyne Therapeutics (DYN) Analyst Rating Update: Target Price Lowe - GuruFocus
Can Dyne Deliver And Achieve Milestones In DMD And Myotonic Dystrophy Trials? - RTTNews
Dyne Therapeutics Narrowed Its Loss And Won Analyst Support - Finimize
Chartists See Breakout Potential in Dyne Therapeutics Inc.Technical Stock Breakout Predictions Signal Entry Points - beatles.ru
Dyne Therapeutics: A High-Conviction Biotech Play with Near-Term Catalysts and a Strengthened Balance Sheet - AInvest
Dyne Therapeutics extends cash runway as it advances key drug programs - Investing.com Nigeria
Dyne Therapeutics, Inc. Q2 Loss Increases, Misses Estimates - Nasdaq
1.02%
3.70%
자본화:
|
볼륨(24시간):